Literature DB >> 4040977

Potential neuroleptic agents. 3. Chemistry and antidopaminergic properties of substituted 6-methoxysalicylamides.

T de Paulis, Y Kumar, L Johansson, S Rämsby, L Florvall, H Hall, K Angeby-Möller, S O Ogren.   

Abstract

A series of substituted 6-methoxysalicylamides were synthesized from their corresponding 2,6-dimethoxybenzamides by demethylation of one methoxy group with boron tribromide. Substituted 6-methoxysalicylamides having a lipophilic aromatic substituent in the 3-position para with respect to the methoxy group, e.g. a bromo or an iodo atom or an ethyl or a propyl group, and having an (S)-N-(1-alkyl-2-pyrrolidinyl)methyl moiety as the side chain were found to be potent blockers of [3H]spiperone binding in vitro and potent inhibitors of the apomorphine syndrome in the rat. Similar to remoxipride but in contrast to haloperidol, some of the substituted salicylamides show a 10-20-fold separation between the dose that inhibits hyperactivity and that which inhibits stereotypy. It was concluded that, besides the requirement of a lipophilic substituent in the position para to the methoxy group for antidopamine activity in vivo, the formation of a coplanar six-membered pseudoring involving the amide moiety and the methoxy group is a structural requirement for activity in vitro.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4040977     DOI: 10.1021/jm00147a025

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  7 in total

Review 1.  A review of the discovery, pharmacological characterization, and behavioral effects of the dopamine D2-like receptor antagonist eticlopride.

Authors:  Jennifer L Martelle; Michael A Nader
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

2.  Agonist signalling properties of radiotracers used for imaging of dopamine D2/3 receptors.

Authors:  Jan-Peter van Wieringen; Martin C Michel; Henk M Janssen; Anton G Janssen; Philip H Elsinga; Jan Booij
Journal:  EJNMMI Res       Date:  2014-10-07       Impact factor: 3.138

3.  The role of dopaminergic transmission through D1-like and D2-like receptors in amphetamine-induced rat ultrasonic vocalizations.

Authors:  Jennifer M Wright; May R S Dobosiewicz; Paul B S Clarke
Journal:  Psychopharmacology (Berl)       Date:  2012-09-28       Impact factor: 4.530

4.  NCQ 298, a new selective iodinated salicylamide ligand for the labelling of dopamine D2 receptors.

Authors:  H Hall; T Högberg; C Halldin; C Köhler; P Ström; S B Ross; S A Larsson; L Farde
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

5.  Effects of remoxipride, a dopamine D-2 antagonist antipsychotic, on sleep-waking patterns and EEG activity in rats and rabbits.

Authors:  E Ongini; P Bo; S Dionisotti; M Trampus; F Savoldi
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

6.  Dosimetry of iodine-123 iodobenzamide in healthy volunteers.

Authors:  N P Verhoeff; E B Sokole; M Stabin; D Hengst; H F Kung; E A Van Royen; A G Janssen
Journal:  Eur J Nucl Med       Date:  1993-09

7.  Structure-based development of caged dopamine D2/D3 receptor antagonists.

Authors:  Marie Gienger; Harald Hübner; Stefan Löber; Burkhard König; Peter Gmeiner
Journal:  Sci Rep       Date:  2020-01-21       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.